PLOD3

Across TCGA pan-cancer cohorts, PLOD3 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of PLOD3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PLOD3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PLOD3 is over-expressed in tumor.

HNSC, KIRC, and COAD are the cancer types where PLOD3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLOD3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	IV	+2.390	<.001	12	view →
KIRC	Male	IV	+1.757	<.001	12	view →
COAD	All	IV	+1.967	<.001	11	view →
KIRP	Male	II,III,IV	+1.584	<.001	11	view →
STAD	Male	III,IV	+2.173	<.001	9	view →
LIHC	Female	II,III,IV	+2.079	<.001	9	view →
LUAD	All	III,IV	+0.738	<.001	8	view →
LUSC	All	All	+0.545	<.001	6	view →
BRCA	All	All	+0.337	<.001	6	view →
CHOL	Female	All	+2.590	<.001	5	view →
READ	All	All	+1.417	<.001	5	view →
BLCA	Female	All	+1.220	.005	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

PLOD3–HNSC

Open the HNSC breakdown →